Literature DB >> 181343

An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

G Klein, B Giovanella, A Westman, J S Stehlin, D Mumford.   

Abstract

An in vitro line was derived from an American Burkitt lymphoma, designated Ra No. 1, which produced malignant tumors when inoculated into thymus-deficient nude mice. The cells have B-lymphocyte characteristics, with surface-associated mu and kappa chains and Epstein-Barr virus (EBV) receptors, and can be readily infected with EBV in vitro. B95-8 virus induced EBV-determined nuclear antigen (EBNA) but not early antigen (EA) in Ra No. 1 cells, whereas P3HR-1 virus induced both EBNA and EA, but the EA level was much lower than in the prototype Raji strain, EBNA and EA levels were comparable in Ra No. 1 and in the previously established, EBV-infection-sensitive BJA-B lymphoma. The two lines differed, however, because BJA-B could be converted into a permanent EBV-carrying line by the B95-8 but not by the P3HR-1 virus strain, whereas Ra No. 1 could be converted by the P3HR-1 virus. This demonstrates that different B-lymphocyte-derived lymphoma lines can vary with regard to the restrictive control they can exert on the same virus strain. Furthermore, virus strains vary in their sensitivity to the restrictions of the same host cell. Permanent EBV conversion of the Ra No. 1 cell did not appear to change the cellular controls, as judged by the unchanged sensitivity of the cell to viral antigen (EA, viral capsid antigen) induction by P3HR-1 virus superinfection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 181343     DOI: 10.1159/000149930

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  131 in total

1.  Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays.

Authors:  R G Jenner; M M Albà; C Boshoff; P Kellam
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  In vivo and in vitro studies of immunoglobulin gene somatic hypermutation.

Authors:  J E Sale; M Bemark; G T Williams; C J Jolly; M R Ehrenstein; C Rada; C Milstein; M S Neuberger
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

3.  Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.

Authors:  R S Harris; D S Croom-Carter; A B Rickinson; M S Neuberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Identification of a family of Fc receptor homologs with preferential B cell expression.

Authors:  R S Davis; Y H Wang; H Kubagawa; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

5.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

6.  Detection of Epstein-Barr virus by in situ hybridization. Progress toward development of a nonisotopic diagnostic test.

Authors:  R Bashir; F Hochberg; R H Singer
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

7.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

8.  A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.

Authors:  B Barnhart; G S Ford; A Bhushan; C Song; L R Covey
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

9.  Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.

Authors:  A Marchini; R Longnecker; E Kieff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  A cell-specific factor represses stimulation of transcription in vitro by transcriptional enhancer factor 1.

Authors:  S Chaudhary; C Brou; M E Valentin; N Burton; L Tora; P Chambon; I Davidson
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.